118 related articles for article (PubMed ID: 21349382)
1. [Ovarian epithelial dysplasia: Description of a dysplasia scoring scheme].
Chene G; Dauplat J; Raoelfils I; Bignon YJ; Cayre A; Jaffeux P; Aublet-Cuvelier B; Pomel C; Penault-Llorca F
Ann Pathol; 2011 Feb; 31(1):3-10. PubMed ID: 21349382
[TBL] [Abstract][Full Text] [Related]
2. [Epithelial ovarian cancer dysplasia: At last a "precancerous" lesion of the ovary!].
Sabourin JC
Ann Pathol; 2011 Feb; 31(1):2. PubMed ID: 21349381
[No Abstract] [Full Text] [Related]
3. Ovarian dysplasia in prophylactic oophorectomy specimens: cytogenetic and morphometric correlations.
Deligdisch L; Gil J; Kerner H; Wu HS; Beck D; Gershoni-Baruch R
Cancer; 1999 Oct; 86(8):1544-50. PubMed ID: 10526284
[TBL] [Abstract][Full Text] [Related]
4. Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer.
Dauplat J; Chene G; Pomel C; Dauplat MM; Le Bouëdec G; Mishellany F; Lagarde N; Bignon YJ; Jaffeux P; Aublet-Cuvelier B; Dechelotte P; Pouly JL; Penault-Llorca F
Eur J Cancer; 2009 Nov; 45(17):2977-83. PubMed ID: 19822418
[TBL] [Abstract][Full Text] [Related]
5. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
7. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
8. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
Lheureux S; Shaw PA; Karakasis K; Oza AM
Gynecol Oncol; 2015 Aug; 138(2):235-7. PubMed ID: 26072440
[No Abstract] [Full Text] [Related]
9. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology.
Kerner R; Sabo E; Gershoni-Baruch R; Beck D; Ben-Izhak O
Gynecol Oncol; 2005 Nov; 99(2):367-75. PubMed ID: 16051332
[TBL] [Abstract][Full Text] [Related]
11. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
12. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
13. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
14. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
15. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ
Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655
[TBL] [Abstract][Full Text] [Related]
16. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
17. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
20. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
